Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | ATM | Q13315 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.76 |
| ▸ | CA12 | O43570 | 3/20 | 0.76 |
| ▸ | CA4 | P22748 | 3/20 | 0.76 |
| ▸ | CA7 | P43166 | 3/20 | 0.76 |
| ▸ | DPP4 | P27487 | 2/20 | 0.76 |
| ▸ | GSK3B | P49841 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosakutanetin SCHEMBL31128790 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Isosakutanetin SCHEMBL5067423 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Isosakutanetin SCHEMBL29358328 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| SCHEMBL16710297 | 0.94 | CYP19A1 (0.90) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| SCHEMBL16710295 | 0.94 | CYP19A1 (0.90) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Isosakutanetin SCHEMBL2146746 | 0.90 | CYP1A1 (0.82) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Naringenin SCHEMBL7668757 | 0.90 | CYP1A1 (0.82) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| SCHEMBL13906136 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Alpinetin SCHEMBL30741428 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Alpinetin SCHEMBL29580312 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1099 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| EP-4655410-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | Symrise AG (DE) | 2025-12-03 | — | — | EP | claimed |
| WO-2025091065-A1 | FLAVONOID COMPOSITION | GRETALS AUSTRALIA PTY LTD (AU) | 2025-05-08 | — | — | WO | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240398752-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CIRRHOSIS COMPRISING ISOSAKURANETIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2024-12-05 | — | — | US | claimed |
| CN-118697017-A | Sweetness and taste improvement of steviol glycoside or mogroside sweetener with flavonoids | 可口可乐公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024156879-A2 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | claimed |
| WO-2024156359-A1 | O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE | SYMRISE AG (DE) | 2024-08-02 | — | — | WO | claimed |
| US-11980184-B2 | Method of making a flavonoid solution and applications thereof for plant growth promotion, seed coating, pathogen elimination, and herbicide stunting effect removal | THE BIO CONSULTING (PTY) LTD (ZA) | 2024-05-14 | — | — | US | claimed |
| US-20040081734-A1 | Method for selectively obtaining antioxidant rich extracts from citrus fruits | QUEEN BIOACTIVES PTY LTD (AU) | 2004-04-29 | — | — | US | claimed |
| US-20040057908-A1 | Oral compositions and use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-03-25 | — | — | US | claimed |
| EP-1399119-A2 | ORAL COMPOSITIONS AND USE THEREOF | University of Rochester (US) | 2004-03-24 | — | — | EP | claimed |
| US-6528099-B1 | Extracts from the cells, frit, core, and peels of citrus fruits, comprises a) employing water treatment and solids extraction of the citrus fruit; b) employing separation technology and/or membrane technology on the extracts, | ADUMIM CHEMICALS LTD. (IL) | 2003-03-04 | — | — | US | claimed |
| WO-2002047615-A2 | ORAL COMPOSITIONS AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2002-06-20 | — | — | WO | claimed |
| EP-1143810-A1 | A METHOD FOR SELECTIVELY OBTAINING ANTIOXIDANT RICH EXTRACTS FROM CITRUS FRUITS | ADUMIM CHEMICALS LTD. (IL) | 2001-10-17 | — | — | EP | claimed |
| US-6183731-B1 | APPLYING COSMETIC WITH BACTERIAL 4-ENE REDUCTASE AND/OR 5A-REDUCTASE INHIBITOR | UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. | 2001-02-06 | — | — | US | claimed |
| WO-2000032062-A1 | A METHOD FOR SELECTIVELY OBTAINING ANTIOXIDANT RICH EXTRACTS FROM CITRUS FRUITS | ADUMIM CHEMICALS LTD. (IL) | 2000-06-08 | — | — | WO | claimed |
| WO-2000001355-A1 | METHOD OF REDUCING OR PREVENTING MALODOUR | UNILEVER PLC (GB) | 2000-01-13 | — | — | WO | claimed |
| US-4105675-A | REDUCING ACYLATED FLAVANONE WITH ALKALI BOROHYDRIDE TO REMOVE OXYGEN FUNCTION AT 4-POSITION; OXIDIZING WITH HALOGENATED BENZOQUINONE TO FORM SALT | THE COCA-COLA COMPANY (US) | 1978-08-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398752-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CIRRHOSIS COMPRISING ISOSAKURANETIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | ALPL, GOT1, GYS2 | CYP1A1 3324/4885CYP1A2 1355/4885CYP1B1 2838/4885 |
| US-20040057908-A1 | Oral compositions and use thereof | UGGT1, DPM1, B4GALT1 | CYP1A1 578/4885CYP1A2 355/4885CYP1B1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.